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Background. The participation of the renin-angiotensin system in the control of blood pressure in normal, sodium-replete subjects is not clear. The use of a specific inhibitor of human renin should allow a better delineation of the importance of this system.
Methods and Results. Blood pressure responses were measured 1 hour after randomized, double-blind administration of the renin inhibitor Ro 42-5892 (600 mg p.o.) or the angiotensin converting enzyme inhibitor captopril (50 mg p.o.) in 20 healthy men on an ad libitum sodium diet. Effective inhibition of the renin-angiotensin system by either compound was indicated by increases of immunoreactive renin associated with an increase of angiotensin I production rate of 67.8+33.6% after captopril and a decrease of 79.5+16.4% after Ro . Furthermore, Ro 42-5892 decreased plasma renin activity by 64%. Whereas intra-arterial diastolic (60+±5.1 to 51.4+7.2 mm Hg, p<0.01) and mean arterial (77.7±6.0 to 71.4+8.5 mm Hg, p<0.001) pressures decreased after captopril, they remained unchanged after Ro . Captopril, but not Ro 42-5892, increased forearm blood flow (2.4±0.8 versus 1.9±0.8 ml/min/100 ml, p <0.01) and significantly enhanced the increase of forearm blood flow to brachial artery infusions of bradykinin (0.15, 1.5, 5, 15, and 50 ng/min/100 ml; 5 minutes each) from 744±632% to 1,383 ±514% (p<0.01). Furthermore, repeat bradykinin infusions resulted in further decreases of blood pressure (from mean pressure of 71.4±8.5 to 63.2±7.6 mm Hg, p<0.01) only after captopril. Changes of blood pressure after captopril were unrelated to baseline plasma renin activity but correlated with captopril-induced enhancement of vasodilation to bradykinin (r=0.68, p<0.05).
Conclusions. The lack of blood pressure effects of renin inhibition in contrast to angiotensin converting enzyme inhibition suggests that the renin-angiotensin system does not contribute significantly to blood pressure control in normotensive, sodium-replete subjects. The hypotensive activity of angiotensin converting enzyme inhibitors may result from additional hormonal effects, for example, inhibition of bradykinin degradation and/or subsequent increases of vasodilating prostaglandins or endothelium-derived relaxing factor(s). (Circulation 1992 26 The monoclonal antibody used does not cross-react with inactive prorenin but cross-reacts fully with active renin even when inhibited. Ro 42-5892 interferes slightly in this assay, but interference was less than 10% at 10 nM, a plasma concentration 10 times higher than the IC50 measured in the plasma assay.20 Angiotensin I production rate was calculated as the ratio of (plasma renin activity control/1 hour) and (plasma immunoreactive renin control/1 hour) and is expressed as percentage change from the control value.
Drugs
The forearm volume of each subject was measured by water displacement according to the Archimedes principle, and drug doses were adjusted accordingly. All solutions were freshly prepared before each study. The nonapeptide bradykinin (Sigma Chemical, St. Louis, Mo.) was diluted in Physiogel (gelatin solution, 4%; molecular weight, 22,000; Swiss Red Cross, Bern, Switzerland) to avoid binding to syringes or tubing. For each subject, six identical-appearing capsules were provided. According to a randomization list, subjects received either one capsule of 50 mg captopril and five capsules filled with cornstarch or six capsules of 100 mg Ro 42-5892. Ro 42-5892 is a transition-state renin inhibitor with the structure the previously used'9,21 drinking solution (C. Kleinbloesem, unpublished observation).
Study Protocol
All studies were performed in the morning with the subjects recumbent and resting comfortably after a light breakfast. All subjects had been asked to refrain from smoking and caffeinated beverages for 8 hours before the study; none was taking medication, and all were on their regular diet, which contains approximately 130-150 mmol Na per day, as shown in previous studies from a similar student and hospital personnel population. 27 The studies were per formed in a quiet, air-conditioned room at an ambient temperature of 20-22°C and lasted for approximately 5 hours. Under local anesthesia (lidocaine 1%), an 18-gauge catheter (Abbocath-T, Abbott, Sligo, Ireland) was inserted into the left brachial artery for regional drug infusion and recording of arterial pressure by a Statham P23 Pb pressure transducer. A second catheter was inserted into a cubital vein for withdrawal of blood for hormone determinations except in three subjects, in whom blood was drawn via the arterial line. The subjects were allowed to rest for 30 minutes after completion of instrumentation; then basal forearm blood flow, intra-arterial blood pressure, and heart rate were recorded, and blood was drawn for renin measurements. Next, bradykinin (0.15, 1.5, 5, 15, and 50 ng/min/100 ml forearm tissue; 5 minutes each) was infused into the brachial artery; forearm blood flow was measured in the last minute of each infusion. Blood pressure and heart rate were recorded immediately after completion of each bradykinin infusion. After completion of the bradykinin infusions, subjects received either 50 mg captopril or Ro 42-5892 p.o. One hour after drug administration, blood pressure, forearm blood flow, and heart rate were measured, and blood was drawn for hormone determinations. Then, bradykinin infusions were repeated in an identical manner, and forearm blood flow, blood pressure, and heart rate were recorded accordingly. Bradykinin infusions were generally well tolerated, but a feeling of warmth associated with a forearm flush was reported by most subjects. The highest dose of bradykinin was omitted in one subject (randomized to captopril) because of discomfort in the infused arm with the second highest dose.
Statistical Analysis
Results are expressed as mean+ SD. One-factor analysis of variance (ANOVA) was used to test for differences attributable to the different drugs. Responses to bradykinin infusions and the influence of captopril and Ro 42-5892, respectively, were analyzed with a two-way profile analysis of repeated measures. The unpaired Student's t test and linear regression analysis were used as appropriate. A twotailed probability value of p<0.05 was considered to indicate a significant difference. All calculations were performed with the STATVIEW II (Abacus Inc., Berkeley, Calif.) statistical program.
Results

Hemodynamic and Hormonal Findings at Rest
The hemodynamic and hormonal findings are summarized in Table 1 . Both drugs significantly increased immunoreactive renin. Plasma renin activity decreased after renin inhibition by 64% on average (range -15 to -92%). As expected from their mode of interference with the renin-angiotensin system, angiotensin I production rate increased after captopril by 67.8% and decreased after renin inhibition by 79 Figure 1 . During control conditions, blood pressure and heart rate were unchanged during bradykinin infusions, whereas forearm blood flow increased dose dependently from 1.9±0.8 to 14.3±7.8 (744%) in subjects randomized to captopril and, similarly, from 2.0±0.5 to 17.6±7.7 ml/min/100 ml (798%) in subjects randomized to Ro 42-5892. The vasodilator response to repeat bradykinin infusions was significantly enhanced by captopril, which increased the maximal response of forearm blood flow to 1,383% (from 2.4±0.8 to 34.1±8.7 ml/min/100 ml). In contrast, Ro 42-5892 did not alter the forearm vasodilator response to bradykinin, which increased maximally by 853% from 2.2±1.1 to 23.0± 12.3 ml/min/100 ml (p<0.001 for difference between captopril-and Ro 42-5892-induced changes; two-factor repeatedmeasures ANOVA). Captopril-induced changes of blood pressure were significantly correlated with the enhancement of the forearm vasodilator response to the highest bradykinin dose (Figure 2) 
Suppression of plasma renin activity varied between subjects and was not complete. Theoretically, this might also contribute to the observed difference. However, blood pressure did not decrease in six subjects in whom plasma renin activity decreased by more than 60% (mean, 79%). This finding and the lack of blood pressure effects of other renin inhibitors, which suppressed plasma renin activity to almost undetectable levels when given intravenously,33-35 make this an unlikely explanation for our findings. The small degree of renin inhibition in some subjects might also be taken as evidence that the bioavailability of Ro 42-5892 may be variable. Ours was not a pharmacokinetic study, so we cannot comment on this aspect. However, immunoreactive renin was increased in all subjects, suggesting blockade of the renin-angiotensin system even in those subjects with low degrees of renin inhibition at the time of measurement. A dissociation between shortlasting renin inhibition and long-lasting elevations of immunoreactive renin has been noted before. 33 Our results also show that renin inhibition did not influence bradykinin metabolism. Reduced bradykinin degradation may be involved in the pathogenesis of angiotensin converting enzyme inhibitor-induced cough15 and angioneurotic edema.'4 Although a kinin-induced increase of prostaglandins rather than increased kinin levels per se may lead to a sensitization of the cough reflex,15 it might nevertheless be anticipated that these unwanted effects would not be present during therapy with renin inhibitors.
Blood Pressure Effects ofAngiotensin Converting Enzyme Inhibitors
Angiotensin converting enzyme inhibition with captopril increased forearm blood flow and reduced blood pressure along with the expected blockade of the renin-angiotensin system, as evidenced by increased immunoreactive renin, plasma renin activity, and, therefore, markedly increased angiotensin I production rate. Because renin inhibition did not change blood pressure, it appears likely that effects unrelated to the renin-angiotensin system accounted for the fall in blood pressure. Captopril-induced changes of blood pressure were caused by peripheral vasodilation, as documented by the relation between increases in forearm blood flow and decreases of mean arterial pressure. Heart rate increased significantly in our subjects, probably resulting from baroreflex-mediated sympathetic stimulation. This finding differs from hypertensive subjects8-0 or patients with heart failure,47 in whom heart rate either does not change or may actually decrease. Although this difference is not readily explained, it may reflect differences in baroreflex function, which presumably was normal in our young, normotensive subjects compared with the depressed function usually observed in patients with hypertension48 or heart fail-ure. Furthermore, this was an acute study, and heart rate responses might differ during long-term therapy.
Captopril significantly enhanced the forearm vasodilator response to brachial artery infusions of bradykinin in our subjects. Although blockade of bradykinin degradation by angiotensin converting enzyme inhibition is expected,49,50 it was interesting to observe that the captopril-induced enhancement of the vasodilator response to bradykinin was related to the decrease of blood pressure. This finding and the lack of a relation between baseline plasma renin activity and blood pressure effects of captopril suggest that the hypotensive response to angiotensin converting enzyme inhibition may be related to an interference with the degradation of bradykinin. The powerful vasodilator activity of the bradykinin system is supported by the observation that low concentrations of this peptide had no effect on blood pressure before captopril administration but significantly and markedly lowered blood pressure after captopril.
Interference with degradation of bradykinin has long been suspected to play a role in the vasodilator activity of angiotensin converting enzyme inhibitors. Plasma bradykinin levels8 and urinary kinin excretion10 were elevated in hypertensive patients, and captopril increased plasma bradykinin levels in patients with congestive heart failure.5' Bradykinin infusion restored the vasodepressor action of teprotide in nephrectomized rats,12 and administration of captopril during renin inhibition in sodium-depleted dogs resulted in an additional decrease of blood pressure, probably explained by an effect of captopril unrelated to reduced angiotensin II levels.52 Most convincingly, infusion of a bradykinin antagonist partially prevented the antihypertensive effect of enalaprilat in rat models of hypertension,13,53 suggesting that at least part of the blood pressure-lowering effect of angiotensin converting enzyme inhibition is mediated by inhibition of the degradation of kinins. Whether this effect results from an increase in tissue kinins acting as autacoids in the regulation of vascular tone or from bradykinin-mediated release of vasodilating prostaglandins54 is less clear. However, there is considerable support for a role of prostaglandins in the vascular response to angiotensin converting enzyme inhibitors. Teprotide increased plasma prostaglandin E concentrations in hypertensive patients,10 and captopril-induced decreases of blood pressure in normal men correlated with increases of 13,14-dihydro-15-keto prostaglandin E2.5 Furthermore, the acute hypotensive effect of captopril was attenuated after inhibition of cyclooxygenase in normotensive and hypertensive subjects,'1 and the peripheral vasodilator effect of captopril was blunted in patients with congestive heart failure after pretreatment with indomethacin along with a complete blockade of captopril-induced increases of prostaglandin E2 and 6-keto-prostaglandin Fla.51 Therefore, both local effects of vascular bradykinin accumulation and systemic increases of vasodilating prostaglandins may be involved in the hemodynamic effects of angiotensin converting enzyme inhibition. Bradykinin also mediates release of EDRF.30,31 Tonic release of EDRF contributes significantly to the control of arteriolar tone in humans,56 and stimulation of EDRF release results in marked vasodilation both in normotensive and, less pronouncedly, in hypertensive subjects.57 '58 There are no data in humans investigating the effects of angiotensin converting enzyme inhibition on the control of arteriolar tone by EDRF, but cilazapril, for example, normalized impaired EDRF-mediated vasodilation in spontaneously hypertensive rats.59 However, it is not clear whether or to what extent this powerful vasodilator system contributes to the antihypertensive effects of angiotensin converting enzyme inhibitors in humans. Finally, it must be reemphasized that this was an acute study performed in salt-replete normotensive subjects. Accordingly, the magnitude of non-angiotensin II-mediated effects of angiotensin converting enzyme inhibitors may be less during long-term therapy, in sodium depletion, or in disease states.
Conclusions
Our results suggest that the renin-angiotensin system does not contribute significantly to the maintenance of blood pressure in normotensive, sodiumreplete subjects and that the hypotensive activity of angiotensin converting enzyme inhibitors, at least in normotensive subjects, may be a result of additional hormonal effects. Use of specific renin inhibitors may be a more appropriate tool than angiotensin converting enzyme inhibitors to study the renin-angiotensin system in humans. This approach may have considerable impact on the design of future studies to assess this system both in normal subjects and in patients with such diseases as primary hypertension or congestive heart failure.
